These drugs include abciximab, eptifibatide, and tirofiban. They very strongly inhibit platelet function by blocking the binding of fibrinogen to the activated glycoprotein IIb/IIIa receptor complex. Any of these agents may be used in addition to aspirin, a thienopyridine and anticoagulation (except with bivalirudin) at the time of PCI in high risk patients with STEMI. They are also used during unstable angina/non-ST elevation MI when PCI is planned. Using glycoprotein IIb/IIIa inhibitors prior to PCI does not have strong data to support its use at the present time.